General AML

Sangmin Lee | ASH 2018 | Luspatercept in MDS


At the 2018 American Society of Hematology (ASH), Sangmin Lee talked about the MEDALIST trial in second-line myelodysplastic syndrome (MDS). The trial met their primary objective of a reduced need for red blood cell transfusions compared to placebo. 

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF
Was this article informative? Thank you for your feedback!